Skip to main content

Table 1 Baseline Characteristics of the Study Participants

From: Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment

Variable

Early therapy n = 88

Delayed therapy n = 62

P value

Age, years

Mean ± SD

34.86 ± 8.1

34.82 ± 7.6

0.97

Gender, number (%):

Male

74 (84.1%)

52 (83.9%)

 

Female

14 (15.9%)

10 (16.1%)

0.971

BMI, kg/m2:

Mean ± SD

17.9 ± 2.8

18.4 ± 2.1

 

Hemoglobin, mg/dl

Mean ± SD

10.6 ± 1.7

11.0 ± 1.9

 

CD4 count, cells/mm3:

Median

133

152

 

(Range)

(7 – 588)

( 14 – 648 )

 

log10viral load/ml:

Median

5.36

5.30

 

(Range)

(2.42–5.88)

(2.33–5.88)

 

Non TB OI’s :

number (%)

12 (13.6%)

10 (16.1%)

0.671

WHO Staging of HIV disease, number (%):

Stage 3

19(21.6%)

15 (24.2%)

0.70

Stage 4

69 (78.4%)

47 (75.8%)

(overall)

Type of Tuberculosis, number (%):

PTB

19 (21.6%)

15 (24.2%)

 

PTB with Dissemination

33 (37.5%)

26 (41.9%)

0.367

EPTB

18 (20.4%)

15 (24.2%)

(overall)

EPTB with Dissemination

18 (20.4%)

06 (09.7%)

 

DOTS Category of ATT, number (%):

Category I (2H3R3Z3E3 + 4H3R3)

83 (94.3%)

61 (98.4%)

0.214

Category II (2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3)

05 (5.7%)

01 (1.6%)

(overall)

  1. SD = Standard deviation; BMI = Body Mass Index; OI’s = Opportunistic Infections; WHO = World Health Organization; HIV = Human immunodeficiency virus; PTB = Pulmonary Tuberculosis; EPTB = Extra Pulmonary Tuberculosis; ATT = Antituberculosis treatment; H = Isoniazid (600 mg), R = Rifampicin (450 mg), Z = Pyrazinamide (1500 mg), E = Ethambutol (1200 mg), S = Streptomycin (750 mg).